Speaker :

Dr. Priya Tiwari, Medical Oncologist, Delhi

Clinical utility of Mamma Print testing in Invasive Lobular Carcinoma: Results from  the MINDACT phase III trial

Author: O. Metzger

 Citation: Ejc,EBCC 12, Volume 138, Supplement 1,S5-S6,OCTOBER 01, 2020

First results from a phase III randomized clinical trial of standard adjuvant endocrine  therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hor mone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with  recurrence score (RS) < 25>

Author: Kevin Kalinsky

 Citation: SABCS 2020 GS3–00

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

Author: Ian Smith

 Citation: The Lancet.,VOLUME 21, ISSUE 11, P1443-1454, NOVEMBER 01, 2020